Integra Expands Wound Care Infrastructure With TEI Buy

With its acquisition of TEI Biosciences, Integra expands its wound management portfolio and sales channels in advances of its planned diabetic foot ulcer product in 2016. The deal, along with the July 1-completed spin out of SeaSpine, fits with Integra's strategy to achieve high single-digit growth.